Group One Trading
ABCL icon

Group One Trading’s AbCellera Biologics ABCL Stock Holding History

Group One Trading’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
88,100
+20,800
+31% +$74.8K ﹤0.01% 3772
2025
Q4 		$230K Sell
67,300
-42,700
-39% -$191K ﹤0.01% 4254
2025
Q3 		$553K Buy
110,000
+75,700
+221% +$334K ﹤0.01% 3611
2025
Q2 		$118K Sell
34,300
-22,900
-40% -$57K ﹤0.01% 4836
2025
Q1 		$128K Buy
57,200
+11,400
+25% +$32.7K ﹤0.01% 4416
2024
Q4 		$134K Buy
45,800
+6,000
+15% +$16.7K ﹤0.01% 4268
2024
Q3 		$103K Buy
39,800
+1,900
+5% +$5.26K ﹤0.01% 4147
2024
Q2 		$112K Buy
37,900
+14,800
+64% +$56K ﹤0.01% 3876
2024
Q1 		$105K Sell
23,100
-3,200
-12% -$16.3K ﹤0.01% 4113
2023
Q4 		$150K Sell
26,300
-72,700
-73% -$337K ﹤0.01% 4124
2023
Q3 		$455K Buy
99,000
+67,300
+212% +$409K ﹤0.01% 3009
2023
Q2 		$205K Buy
31,700
+3,300
+12% +$22.5K ﹤0.01% 3905
2023
Q1 		$214K Sell
28,400
-17,400
-38% -$158K ﹤0.01% 3605
2022
Q4 		$464K Sell
45,800
-68,700
-60% -$794K ﹤0.01% 3109
2022
Q3 		$1.13M Sell
114,500
-2,700
-2% -$29.6K ﹤0.01% 2445
2022
Q2 		$1.25M Buy
117,200
+69,300
+145% +$587K ﹤0.01% 2536
2022
Q1 		$467K Sell
47,900
-158,200
-77% -$1.5M ﹤0.01% 3884
2021
Q4 		$2.95M Buy
206,100
+5,600
+3% +$85K ﹤0.01% 2200
2021
Q3 		$4.02M Buy
200,500
+152,600
+319% +$2.7M ﹤0.01% 1926
2021
Q2 		$1.05M Buy
47,900
+47,500
+11,875% +$1.31M ﹤0.01% 3352
2021
Q1 		$14K Buy
+400
New +$15.9K ﹤0.01% 6895

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading's ABCL Position: Q1 2026 in Review

Group One Trading increased its AbCellera Biologics (ABCL) stake by 85% in Q1 2026, buying an estimated $396K and bringing the position to 239,133 shares worth $835K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Group One Trading first reported a position in ABCL in Q2 2021 and has held it in 18 quarters since. The position peaked at $1.21M in Q4 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Group One Trading held 239,133 shares of AbCellera Biologics worth $835K as of Q1 2026.
  • Group One Trading bought 110,134 AbCellera Biologics shares in Q1 2026, an estimated $396K.
  • AbCellera Biologics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2878 holding.
  • Group One Trading first reported a position in AbCellera Biologics in Q2 2021 and has held it in 18 quarters since.
  • Group One Trading's AbCellera Biologics position peaked at $1.21M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.